↓ Skip to main content

Dove Medical Press

Impact of potential inappropriate NSAIDs use in chronic pain

Overview of attention for article published in Drug Design, Development and Therapy, April 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter
6 X users

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
99 Mendeley
Title
Impact of potential inappropriate NSAIDs use in chronic pain
Published in
Drug Design, Development and Therapy, April 2015
DOI 10.2147/dddt.s80686
Pubmed ID
Authors

S Ussai, L Miceli, F E Pisa, R Bednarova, A Giordano, G Della Rocca, R Petelin

Abstract

Pain remains one of the main reasons for medical consultation worldwide: moderate- to severe-intensity pain occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives. Nonsteroidal anti-inflammatory drugs (NSAIDs) are not recommended for long-term use and a careful surveillance to monitor for toxicity and efficacy is critical. This study aims to assess: 1) the pattern of use of NSAIDs and opioids in a population covered by a cloud-based pharmacovigilance surveillance system; and 2) potential inappropriate use. A retrospective 18-months systematic analysis on patients' pain treatment was performed. The primary endpoint was evaluating the prevalence of NSAIDs and opioids use and the duration of therapy regimen. The secondary endpoint was to investigate the prevalence of NSAIDs taken for >21 consecutive days concomitant with drugs for peptic ulcer and gastroesophageal reflux disease (GORD) or antiplatelet drugs. The yearly cost for individual users of concomitant NSAIDs for more than 21 consecutive days and of GORD medications has been estimated. A total of 3,050 subjects with chronic pain were enrolled; 97% of them took NSAIDs for >21 consecutive days; about one-fourth of these users also received drugs for peptic ulcer and GORD (Anatomical Therapeutic Chemical code A02B). The yearly cost foran individual who uses NSAIDs for >21 consecutive days as well as concomitant GORD medications is 61.23 euros. In total, 238 subjects (8%) using NSAIDs for >21 days also received one antiplatelet agent. About 11% of subjects received opioids at least once and only 2% of them carried on the therapy for more than 90 consecutive days. In evaluating the escalation in dosage as a proxy of dependence risk, this study shows no dosage escalation in our cohort of chronic pain population - that is to say we show no risk of dependence.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Italy 1 1%
Australia 1 1%
Unknown 96 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 17 17%
Student > Master 16 16%
Researcher 12 12%
Student > Ph. D. Student 11 11%
Other 6 6%
Other 11 11%
Unknown 26 26%
Readers by discipline Count As %
Medicine and Dentistry 27 27%
Nursing and Health Professions 10 10%
Pharmacology, Toxicology and Pharmaceutical Science 10 10%
Biochemistry, Genetics and Molecular Biology 5 5%
Psychology 5 5%
Other 14 14%
Unknown 28 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2016.
All research outputs
#14,277,392
of 25,373,627 outputs
Outputs from Drug Design, Development and Therapy
#759
of 2,268 outputs
Outputs of similar age
#128,495
of 279,166 outputs
Outputs of similar age from Drug Design, Development and Therapy
#34
of 83 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,166 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.